Biogen Inc. will move beyond neurological, rare and autoimmune diseases and into ophthalmology with its planned acquisition of UK-based Nightstar Therapeutics PLC, thereby getting two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.
Biogen on March 4 said it was buying the gene therapy biotech for about $877m in cash, and that the offer price of $25.50 per share represented a premium of 68% to Nightstar’s previous closing price of $15.16
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?